THE FRONTIER MEDICAL AI LAB / EST. 2025

Building towards openmedical superintelligence forclinicians

Multimodal foundation models for medicine. Open weights. Evaluated publicly. Built with the community.

§ 01OUR VISION

Building a universal
medical foundation model.

Working toward a unified, multimodal understanding of patient state.

1
Input patient data
Unify every modality
📋
Clinical Notes

Visits, history, symptoms

🧪
Labs

Blood, urine, chemistry

🩻
Imaging

X-ray, CT, MRI

🔬
Pathology

H&E, IHC, slides

💓
Signals

ECG, wearables

🧬
Genomics

DNA, RNA, proteomics

💊
Medications

Treatments, response

👤
Demographics

Lifestyle, context

2
Universal medical AI
Learn functional biology of patient state
3
Clinical applications
Predict and intervene

Model disease trajectory

Predict how a patient's state evolves over time and their risk of adverse outcomes.

Predict intervention response

Identify interventions that can move a patient toward a healthier state.

Accelerate biomedical research

Generate clinically grounded hypotheses from multiscale, longitudinal patient representations.

§ 02RESEARCH

Pushing the frontier with open models and rigorous benchmarking

Explore our available models, benchmark leaderboards, and active open challenges.

§ 03COMMUNITY

Open science
community.

MedARC is the world's largest open medical AI research community — founded by Sophont's CEO and home to thousands of researchers, clinicians, and engineers.

MedARC
Community

MedARC

The world's largest open medical AI research community.

What happens in MedARC
Open collaborative research projects
Regular journal clubs and reading groups
Shared compute and dataset access
Direct access to Sophont researchers
4,000+
Community members
10
Published papers
Journal Club

Join the next discussion.

We invite researchers to present their work, then open the room for discussion with the community. Add the series to your calendar, or sign up below for email notifications.

§ 04SOLUTIONS

Open models drive
clinical applications.

We develop commercial products with pharma, hospitals, and medtech teams, translating our open-source models into clinically relevant applications.

IN DEVELOPMENT

Coming Soon

Our first commercial product is in active development with clinical, biopharma, and life sciences partners. We'll announce more when it's ready — with rigorous validation.

Contact us to learn more
Stay tuned
§ 05PUBLICATIONS

Publications.

Selected peer-reviewed papers, workshop contributions, and technical reports from the Sophont and MedARC research collective.

Jun 2026

Compress-Distill: Reasoning Trace Compression for Efficient Knowledge Distillation

M. Griot, P.S. Scotti, T.M. Abraham
arXiv
May 2026

Medmarks: A comprehensive open-source LLM benchmark suite for medical tasks

B. Warner, R.S. Grandhi, M. Kieffer, ..., C. Lane, P.S. Scotti, T.M. Abraham
ICML Workshop
May 2026

Scaling Vision Transformers for Functional MRI with Flat Maps

C. Lane, M. Tripathy, L.K. Murali, R.S. Grandhi, ..., D.Z. Kaplan, B. Warner, T.M. Abraham, P.S. Scotti
ICML
Dec 2025

MIRAGE: Robust multi-modal architectures translate fMRI-to-image models from vision to mental imagery

R. Kneeland, C. Torrico, T. Chen, J.A. Ojeda, S. Khanna, J. Xu, P.S. Scotti, T. Naselaris
DBM 2025 Findings
Nov 2025

OpenMidnight: How to Train a State-of-the-Art Pathology Foundation Model with $1.6k

D. Kaplan, R.S. Grandhi, C. Lane, B. Warner, T.M. Abraham, P. Scotti
Sophont TR
Jun 2025

NSD-Imagery: A benchmark dataset for fMRI mental imagery

R. Kneeland, P.S. Scotti, G. St-Yves, J. Breedlove, K. Kay, T. Naselaris
CVPR
Jul 2024

MindEye2: Shared-Subject Models enable fMRI-to-Image with 1 hour of data

P.S. Scotti, M. Tripathy, C. Torrico, R. Kneeland, T. Chen, ..., T.M. Abraham
ICML
Aug 2024

A vision–language foundation model for realistic chest X-ray generation

C. Bluethgen, P. Chambon, J.-B. Delbrouck, ..., T.M. Abraham, S. Purohit, C.P. Langlotz, A.S. Chaudhari
Nature Biomed. Eng.
Jan 2024

CheXAgent: A vision-language foundation model to enhance efficiency of chest X-ray interpretation

Z. Chen, M. Varma, J. Xu, ..., C. Bluethgen, T.M. Abraham, ..., J.-B. Delbrouck, A.S. Chaudhari, C.P. Langlotz
arXiv
Dec 2023

Reconstructing the mind’s eye: fMRI-to-image with contrastive learning

P.S. Scotti, A. Banerjee, J. Goode, ..., K.A. Norman, T.M. Abraham
NeurIPS Spotlight
§ 06TEAM

Built by researchers
from the field.

A small team of medical AI researchers with roots in academic hospitals, open-source ML, and NeuroAI.

Tanishq Mathew Abraham, Ph.D.

Tanishq Mathew Abraham, Ph.D.

CEO & Co-Founder

Former Research Director at Stability AI; founded MedARC, the world’s largest online medical AI research community. Graduated at 19 with a Ph.D. in Biomedical Engineering at University of California, Davis.

Paul Scotti, Ph.D.

Paul Scotti, Ph.D.

CTO & Co-Founder

Former Head of NeuroAI at Stability AI and postdoc at Princeton University. Paul brings over a decade of experience in computational neuroscience.

Hassan Muhammad, Ph.D.

Hassan Muhammad, Ph.D.

Head of Applied Research

Previously Senior Director of AI at Pathomiq and Research Scientist at Memorial Sloan Kettering Cancer Center. Ph.D. from Weill Cornell Medicine

The listed profiles are joined by a broader founding group of scientists and engineers spanning LLMs, NeuroAI, and medical AI.

§ 07PRESS

In the press.

Selected coverage and appearances.

§ 08BACKED BY

Our investors.

We are fortunate to partner with investors and strategic allies across medicine, AI research, and venture.

Delphi VenturesDelphi Ventures
Upfront Ventures
Factorial Capital
Headwater Ventures
AICONIC Ventures
Brightwing CapitalBrightwing Capital
Select angel investors
Jeff Dean

Jeff Dean

Google Chief Scientist

Logan Kilpatrick

Logan Kilpatrick

Google DeepMind

Clem Delangue

Clem Delangue

Hugging Face CEO via Factorial Capital

Lukas Biewald

Lukas Biewald

Weights & Biases co-founder

Mei Zuo

Mei Zuo

Mei Ventures

§ 11 — PARTNER

Let's build the open future of medicine.

We partner with healthcare providers, biopharma and life sciences companies, research institutions, and mission-aligned investors.